-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Candel Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2020 to Q3 2025.
- Candel Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was $1.94M.
- Candel Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was $17.9M.
- Candel Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was -$21.8M, a 4924% decline from 2023.
- Candel Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $452K, a 97.2% decline from 2022.
- Candel Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $15.9M.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)